Payment overview · 2025
General Payments
$1,729.75
102 reported records · 25 companies
Healthcare provider profile · identity verified
Stephen J. Swartz, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HOLMDEL, NJ · NPI 1245211705
Verified facts
What the public records show
CMS Open Payments records show Stephen J. Swartz, M.D. received $1,729.75 in general payments during 2025 across 102 reported records.
AstraZeneca Pharmaceuticals LP accounted for 11.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Nexletol, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta, Verquvo, Voquezna.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Farxiga by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Nexletol by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Mounjaro by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Verquvo by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Paxlovid by this doctor in 2024.
Phathom Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VOQUEZNA as an associated drug or biological on 90302 records involving 33442 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Voquezna by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $204.95 | 11.8% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $172.15 | 9.9% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $141.78 | 8.2% | 16 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $141.78 | 8.2% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $136.09 | 7.9% | 8 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $135.87 | 7.8% | 8 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $71.34 | 4.1% | 4 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $69.43 | 4.0% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $67.10 | 3.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $56.37 | 3.3% | 3 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $55.77 | 3.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $53.10 | 3.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.41 | 3.0% | 3 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $52.28 | 3.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.56 | 2.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $42.66 | 2.5% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $36.88 | 2.1% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.53 | 2.1% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $30.49 | 1.8% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $29.97 | 1.7% | 1 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $28.77 | 1.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.75 | 1.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.71 | 1.0% | 1 | 2025 |
| CashFlow Solutions, LLC | Unresolved — no canonical attribution shown | $13.51 | 0.8% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $13.50 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,729.75 | 102 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $160.06 | 6 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $141.78 | 10 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $136.09 | 8 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $135.87 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $102.54 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $87.25 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $86.96 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $84.21 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $84.21 | 5 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $71.34 | 4 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $69.43 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $67.10 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $56.37 | 3 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $55.77 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $54.82 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $53.10 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $53.10 | 3 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $52.28 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $48.56 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $42.66 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $36.88 | 2 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $36.53 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.01 | 3 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $35.80 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $34.96 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $30.49 | 2 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $29.97 | 1 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $28.77 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| LYMPHA PRESS OPTIMAL PLUS(US) BT Normalized: lympha press optimal plus us bt |
Device | CashFlow Solutions, LLC | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| PCD-51 731A (US) - White Normalized: pcd 51 731a us white |
Device | CashFlow Solutions, LLC | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| PCD-52 737A (US) White Normalized: pcd 52 737a us white |
Device | CashFlow Solutions, LLC | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 116 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 70 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 35 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 100 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 52 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 45 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 78 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VOQUEZNA voquezna |
2025 | Voquezna | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 15 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
70 | 20 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
78 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
203 | 32 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
100 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
45 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
52 | 49 |
| Phathom Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | VOQUEZNA open payments reported associated product |
CMS Open Payments — General Payments 90302 supporting records · 33442 recipient NPIs · example record 1219216983 |
Voquezna · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 697 | 209 |
| Levothyroxine Sodium | Levothyroxine Sodium | 405 | 116 |
| Alprazolam | Alprazolam | 391 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 348 | 115 |
| Metoprolol Succinate | Metoprolol Succinate | 343 | 103 |
| Methylprednisolone | Methylprednisolone | 336 | 196 |
| Atorvastatin Calcium | Atorvastatin Calcium | 329 | 105 |
| Furosemide | Furosemide | 280 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 272 | 91 |
| Tamsulosin Hcl | Tamsulosin Hcl | 263 | 82 |
| Metformin Hcl | Metformin Hcl | 243 | 84 |
| Prednisone | Prednisone | 235 | 114 |
| Cephalexin | Cephalexin | 233 | 147 |
| Nebivolol Hcl | Nebivolol Hcl | 214 | 44 |
| Mounjaro | Tirzepatide | 203 | 32 |
| Valsartan | Valsartan | 187 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 186 | 60 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 184 | 122 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 61 |
| Gabapentin | Gabapentin | 168 | 51 |
| Losartan Potassium | Losartan Potassium | 152 | 51 |
| Citalopram Hbr | Citalopram Hydrobromide | 138 | 31 |
| Omeprazole | Omeprazole | 138 | 41 |
| Potassium Chloride | Potassium Chloride | 138 | 36 |
| Montelukast Sodium | Montelukast Sodium | 132 | 37 |
| Simvastatin | Simvastatin | 128 | 30 |
| Terazosin Hcl | Terazosin Hcl | 122 | 34 |
| Sertraline Hcl | Sertraline Hcl | 121 | 36 |
| Eliquis | Apixaban | 116 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 52 |
| Carvedilol | Carvedilol | 106 | 31 |
| Clonazepam | Clonazepam | 104 | 25 |
| Ozempic | Semaglutide | 100 | 29 |
| Enalapril Maleate | Enalapril Maleate | 98 | 22 |
| Glipizide | Glipizide | 92 | 27 |
| Glipizide Er | Glipizide | 88 | 23 |
| Betamethasone Sod Phos-Acetate | Betamethasone Acetate,sod Phos | 86 | 56 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 86 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 24 |
| Xarelto | Rivaroxaban | 82 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 25 |
| Azithromycin | Azithromycin | 78 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 78 | 28 |
| Allopurinol | Allopurinol | 76 | 24 |
| Januvia | Sitagliptin Phosphate | 76 | 22 |
| Ezetimibe | Ezetimibe | 70 | 24 |
| Farxiga | Dapagliflozin Propanediol | 70 | 20 |
| Spironolactone | Spironolactone | 70 | 19 |
| Donepezil Hcl | Donepezil Hcl | 65 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 62 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | 19 |
| Trazodone Hcl | Trazodone Hcl | 55 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | 13 |
| Tramadol Hcl | Tramadol Hcl | 54 | 16 |
| Jardiance | Empagliflozin | 53 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 52 | 49 |
| Betamethasone Valerate | Betamethasone Valerate | 51 | 28 |
| Methenamine Hippurate | Methenamine Hippurate | 51 | 16 |
| Candesartan Cilexetil | Candesartan Cilexetil | 50 | 11 |
| Lisinopril | Lisinopril | 50 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 39 |
| Mirtazapine | Mirtazapine | 48 | 13 |
| Finasteride | Finasteride | 45 | 14 |
| Rybelsus | Semaglutide | 45 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | suppressed |
| Synthroid | Levothyroxine Sodium | 44 | 15 |
| Clonidine | Clonidine | 43 | suppressed |
| Famotidine | Famotidine | 43 | 16 |
| Digoxin | Digoxin | 39 | 12 |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | 12 |
| Temazepam | Temazepam | 38 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | 13 |
| Midodrine Hcl | Midodrine Hcl | 36 | 13 |
| Nexletol | Bempedoic Acid | 35 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 23 |
| Memantine Hcl | Memantine Hcl | 33 | 11 |
| Amoxicillin | Amoxicillin | 32 | 21 |
| Lorazepam | Lorazepam | 32 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 13 |
| Atenolol | Atenolol | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 21 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | 15 |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 28 | 22 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 26 | 17 |
| Fluconazole | Fluconazole | 26 | 15 |
| Folic Acid | Folic Acid | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Voquezna | Vonoprazan Fumarate | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 13 |
| Levofloxacin | Levofloxacin | 25 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Livalo | Pitavastatin Calcium | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 12 |
| Modafinil | Modafinil | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Nystop | Nystatin | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Propylthiouracil | Propylthiouracil | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Verquvo | Vericiguat | 13 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Sirolimus | Sirolimus | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Dalfampridine Er | Dalfampridine | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,729.75 · 102 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AMYVID, Arikayce, BREZTRI, Brinsupri, Cologuard Collection Kit, ELIQUIS, Exablate, FARXIGA, FREESTYLE LIBRE 3, Flector, GEMTESA, HORIZANT, Hillrom - Carnation Ambulatory Monitor, JOURNAVX, KISUNLA, Kerendia, LYMPHA PRESS OPTIMAL PLUS(US) BT, Leqembi, Licart, NEXLETOL, OTEZLA, Ohtuvayre, Ozempic, PAXLOVID, PCD-51 731A (US) - White, PCD-52 737A (US) White, QULIPTA, REPATHA, Rybelsus, SKYCLARYS, TRELEGY ELLIPTA, Tirosint, UBRELVY, VERQUVO, VOQUEZNA, VRAYLAR, XIFAXAN | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error